
Rezolute (RZLT) Stock Forecast & Price Target
Rezolute (RZLT) Analyst Ratings
Bulls say
Rezolute Inc continues to demonstrate promising advancements in its clinical pipeline, particularly in the management of congenital hyperinsulinism, as evidenced by significant reductions in hypoglycemia events in trials. A particularly noteworthy outcome from the Phase 2b RIZE study indicates a remarkable 70-90% reduction in weekly hypoglycemia events with the company's drug candidates, supporting the efficacy of their therapies. Additionally, the favorable safety profile of ersodetug, along with the potential for positive regulatory outcomes, strengthens the positive outlook for the company's future revenue and value creation.
Bears say
Rezolute Inc faces significant challenges following the failure of its lead candidate, Ersodetug, which did not demonstrate a statistically significant benefit compared to placebo, leaving both the company and investors disappointed. Additionally, the sunRIZE trial missed key secondary endpoints, highlighting the difficulties in measuring treatment efficacy in an outpatient setting where patient behavior may affect results. The company operates in a high-risk environment characterized by clinical trial uncertainties, regulatory hurdles, and a competitive market landscape, all of which negatively impact its revenue potential and overall stock outlook.
This aggregate rating is based on analysts' research of Rezolute and is not a guaranteed prediction by Public.com or investment advice.
Rezolute (RZLT) Analyst Forecast & Price Prediction
Start investing in Rezolute (RZLT)
Order type
Buy in
Order amount
Est. shares
0 shares